DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Psoriatec (Anthralin) - Published Studies

 
 



Psoriatec Related Published Studies

Well-designed clinical trials related to Psoriatec (Anthralin)

Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. [2005]

Effect of H1-receptor blockade on anthralin inflammation. [1992]

Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis. [1988.04]

Well-designed clinical trials possibly related to Psoriatec (Anthralin)

Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. [2010.06]

A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. [2008.02]

A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. [2007]

A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. [2006.10]

The effect of treatment on quality of life in psoriasis patients. [2005]

Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis. [2004.05]

Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. [2004.03]

Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. [2003.12]

Soluble tumor necrosis factor-alpha receptor type 1 during selenium supplementation in psoriasis patients. [2003.10]

Twice-daily vs. once-daily inpatient dithranol for psoriasis. [2002.11]

Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. [2002.09]

Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. [2002.07]

Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. [2002]

Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. [2001.04]

Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. [2000.05]

The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. [2000]

[Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis] [1999.10]

Effects of Mahonia aquifolium ointment on the expression of adhesion, proliferation, and activation markers in the skin of patients with psoriasis. [1999.04]

A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. [1998.12]

Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis. [1998.05]

[Mometasone and calcipotriol optimize the initial therapeutic effect of dithranol in chronic persistent psoriasis] [1998.04]

Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. [1995.01]

Remission of ordinary psoriasis following a short clearance course of cyclosporin. [1995.01]

Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis. [1993.02]

One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study. [1992.11]

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. [1992.09]

Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. [1992]

Successful treatment of therapy-resistant atopic dermatitis with clobetasol propionate and a hydrocolloid occlusive dressing. [1992]

The effect of oral indomethacin on psoriasis treated with the Ingram regime. [1991.09]

[The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis] [1990.03]

Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP). [1989.04]

Clinical response and side-effects in the treatment of psoriasis with UV-B and -A novel dithranol formulation. [1989]

Double-blind comparison of a dithranol and steroid mixture with a conventional dithranol regimen for chronic psoriasis. [1988.11]

Effect of UVB therapy and a coal tar bath on short contact dithranol treatment for psoriasis. [1988.06]

The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. [1988]

Other research related to Psoriatec (Anthralin)

An EPR method for estimating activity of antioxidants in mouse skin using an anthralin-derived radical model. [2010.03]

Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy. [2009.12]

Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. [2004.01]

Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. [2003.01]

Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese patients. [2000.07]

The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration. [1999.09]

Old wine in new bottles: the revival of anthralin. [1998.10]

Topical anthralin therapy for refractory nail psoriasis. [1998.04]

A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. [1998.01]

Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. [1997.05.09]

Tars and anthralins. [1995.10]

Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. [1995.10]

Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. [1994.08.15]

Anthralin: how does it act and are there more favourable derivatives? [1994]

A semiempirical computational investigation of the antipsoriatic drug anthralin. [1992.11]

The effect of indomethacin on anthralin inflammation. [1992.03]

Development of anthralin short-contact therapy in psoriasis: survey of published clinical trials. [1992.02]

The antipsoriatic drug, anthralin, inhibits protein kinase C--implications for its mechanism of action. [1992]

Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy. [1991.11]

Dithranol (anthralin)-induced skin irritation in C57BL/6, NMRI and SENCAR mice. [1991.08]

UVABA therapy for psoriasis. Efficacy with shortened treatment times with the combined use of coal tar, anthralin, and metal halide ultraviolet machines. [1991.04]

Characteristics and modulation of dithranol (anthralin)-induced skin irritation in the mouse ear model. [1991]

Suppression of footpad reaction in mice by anthralin. [1990.12]

Practical aspects of anthralin therapy. [1990.10]

[Effect of an anthralin-containing hydrocolloid dressing in psoriasis vulgaris] [1990.08]

Studies on the contact sensitizing activity of dithranol (anthralin) and 10-butyryl dithranol (butantrone). [1990.08]

The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. [1990.07]

Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. [1990.06]

Reduction of anthralin-induced inflammation by application of amines. [1990.05]

The influence of salicylic acid on the in vitro release of anthralin from an o/w cream. [1990]

"Ditrawash"--a novel remover of dithranol (anthralin) for short contact therapy of psoriasis. [1989]

Calmodulin inhibition by anthralin? Investigations in vitro and in vivo. [1989]

Inhibition by retinoids of anthralin-induced mouse epidermal ornithine decarboxylase activity and anthralin-promoted skin tumor formation. [1987.12.01]

Evaluation of anthralin in the treatment of alopecia areata. [1987.11]

Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug. [1987.11]

Other possibly related research studies

[Dithranol in the treatment of scalp psoriasis] [2003.09]

Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. [2005.04]

Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. [2005.07]

A clinician's paradigm in the treatment of psoriasis. [2005.07]

Topical therapies for psoriasis: evidence-based review. [2005.04]

[Health economic aspects of psoriasis therapy. Is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints?] [2005.06]

Dithranol irritation in psoriasis treatment: a study of 68 inpatients. [2005.03]

RNase P: a promising molecular target for the development of new drugs. [2004.11]

Physiological variation in the erythemal response to ultraviolet radiation and photoadaptation. [2004.11]

Linear naevoid psoriasis along lines of Blaschko. [2004.11]

Calcipotriol cream in the treatment of flexural psoriasis. [2003]

Interleukin 4 plasma levels in psoriasis vulgaris patients. [2004.04]

Plasma transforming growth factor beta1 as a biomarker of psoriasis activity and treatment efficacy. [2003.09]

Old wine in new bottles: reviving old therapies for alopecia areata using rodent models. [2003.10]

Recalcitrant psoriasis vulgaris associated with Laurence-Moon-Biedl syndrome. [2003.09]

Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay. [2003.01]

Lack of upregulation of epidermal fatty acid binding protein in dithranol induced irritation. [2003.05]

Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis. [2003.04]

[Influence of dithranol therapy on clinical status and serum calcitonin concentrations in patients with common psoriasis] [2002.12]

[Phototherapy and photochemotherapy of inflammatory dermatoses] [2003.02.20]

A systematic review of adverse effects associated with topical treatments for psoriasis. [2003.02]

The topical treatment of psoriasis. [2003.03]

The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis. [2003.01]

The potential of the essential fatty acid-deficient hairless rat as a psoriasis screening model for topical anti-proliferative drugs. [2002.11]

An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated applications of high-dose dithranol cream. [2002.11]

A novelliposomal formulation of dithranol for psoriasis: preliminary results. [2002.08]

[Alopecia areata: update on therapy] [2002.05]

The response of normal human skin to single and repeated applications of dithranol cream: an immunohistochemical assessment. [2002.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014